Compare Wahed FTSE USA Shariah ETF (HLAL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Wahed FTSE USA Shariah ETF trades at $76.37 (market cap $996.16M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 7.5× Wahed FTSE USA Shariah ETF's market cap, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 67 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HLAL | SYRE | |
|---|---|---|
Market Cap | $996.16M | $7.52B |
Volume | 36,084 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $108.92 |
52-Week Low | $57.46 | $22.18 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $75.90, showing modest daily gains of 0.13% with a bullish technical outlook supported by moving averages. The stock faces resistance near $77-78 while finding support at $75-74 levels. Key technical indicators show mixed signals with RSI suggesting potential overbought conditions on shorter timeframes.
Investment outlook remains data-dependent given limited fundamental information availability. The technical setup suggests near-term upside potential if resistance levels are breached, though momentum indicators warrant caution. Investors should await upcoming financial disclosures for clearer fundamental assessment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
